A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multi-center study evaluating the efficacy and safety of four doses of SR 147778 in obese patients
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Surinabant (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Sanofi
- 07 Jun 2017 Biomarkers information updated
- 07 Jul 2009 Actual patient number (394), additional trial locations added as reported by ClinicalTrials.gov.
- 07 Jul 2009 Actual end date (Nov 2005) added as reported by ClinicalTrials.gov.